GUIDE-IBD

Harris, D. M. M., S. Szymczak, S. Schuchardt, J. Labrenz, F. Tran, L. Welz, H. Graßhoff, H. Zirpel, M. Sümbül, M. Oumari, N. Engelbogen, R. Junker, C. Conrad, D. Thaçi, N. Frey, A. Franke, S. Weidinger, B. Hoyer, P. Rosenstiel, S. Waschina, S. Schreiber, and K. Aden (2024). "Tryptophan degradation as a systems phenomenon in inflammation – an analysis across 13 chronic inflammatory diseases." eBioMedicine 102: 105056. doi.org/10.1016/j.ebiom.2024.105056.

Kovar, C., H. L. H. Loer, S. Rüdesheim, L. M. Fuhr, F. Z. Marok, D. Selzer, M. Schwab, and T. Lehr (2024). "A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions." CPT: Pharmacometrics Syst. Pharmacol. 13(7): 1144–1159. doi.org/10.1002/psp4.13146.

Loer, H. L. H., C. Kovar, S. Rüdesheim, F. Z. Marok, L. M. Fuhr, D. Selzer, M. Schwab, and T. Lehr (2024). "Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug–drug interaction predictions." CPT: Pharmacometrics Syst. Pharmacol. 13(6): 926–940. doi.org/10.1002/psp4.13127.

Bokemeyer, B., S. Plachta-Danielzik, R. di Giuseppe, U. Helwig, N. Teich, C. Schmidt, P. Hartmann, C. Sobotzki, and S. Schreiber (2023). "Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study." Aliment Pharmacol Ther .   https://doi.org/10.1111/apt.17512.

Marok, F. Z., J.-G. Wojtyniak, L. M. Fuhr, D. Selzer, M. Schwab, J. Weiss, W. E. Haefeli, and T. Lehr (2023). "A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators." Pharmaceutics 15(2): 679.  doi.org/10.3390/pharmaceutics15020679.

Kovar, C., L. Kovar, S. Rüdesheim, D. Selzer, B. Ganchev, P. Kröner, S. Igel, R. Kerb, E. Schaeffeler, T. E. Mürdter, M. Schwab, and T. Lehr (2022). "Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling." Pharmaceutics 14(12): 2604. doi.org/10.3390/pharmaceutics14122604.

Schrapel, C., L. Kovar, D. Selzer, U. Hofmann, F. Tran, W. Reinisch, M. Schwab and T. Lehr (2021). "External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease." Pharmaceutics 13(9). GUIDE-IBD www.ncbi.nlm.nih.gov/pubmed/34575443.

Türk, D., L. M. Fuhr, F. Z. Marok, S. Rüdesheim, A. Kühn, D. Selzer, M. Schwab and T. Lehr (2021). "Novel models for the prediction of drug–gene interactions." Expert Opin Drug Metab Toxicol 17(11): 1293–1310. GUIDE-IBD doi.org/10.1080/17425255.2021.1998455.

Wojtyniak, J.-G., D. Selzer, M. Schwab and T. Lehr (2021). "Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis." Clin Pharmacol Ther 109(1): 201–211. GUIDE-IBD doi.org/10.1002/cpt.2111.

Kovar, L., C. Schraepel, D. Selzer, Y. Kohl, R. Bals, M. Schwab, and T. Lehr (2020). "Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates." PHARMACEUTICS 12(6). doi.org/10.3390/pharmaceutics12060578.

Rüdesheim, S., J.-G. Wojtyniak, D. Selzer, N. Hanke, F. Mahfoud, M. Schwab, and T. Lehr (2020). "Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions." Pharmaceutics 12(12): 1200. doi.org/10.3390/pharmaceutics12121200.